Start Date

2022

Description

Bacterial resistance to antibiotics is a growing public health threat. Each year, more than 2.8 million antibioticresistant infections occur in the United States and 35,000 people die as a consequence. Fluoroquinolone (FQ) agents targeting the essential bacterial type II topoisomerases DNA gyrase and topoisomerase IV, exemplified by ciprofloxacin, have been in clinical use since the 1980’s and shown to be useful antibiotics. Unfortunately, heavy use of the FQs has inevitably led to the development of FQ-resistant pathogens

Share

COinS
 
Jan 1st, 12:00 AM

An Approach to the Synthesis of 3-Quinazolinedione Carboxylic Acids: Putative Antibiotics

Bacterial resistance to antibiotics is a growing public health threat. Each year, more than 2.8 million antibioticresistant infections occur in the United States and 35,000 people die as a consequence. Fluoroquinolone (FQ) agents targeting the essential bacterial type II topoisomerases DNA gyrase and topoisomerase IV, exemplified by ciprofloxacin, have been in clinical use since the 1980’s and shown to be useful antibiotics. Unfortunately, heavy use of the FQs has inevitably led to the development of FQ-resistant pathogens